epimab.com Open in urlscan Pro
47.241.173.242  Public Scan

Form analysis
0 forms found in the DOM

Text Content

EN
CN
 * Who We Are
   About EpimAb Management Team Board of Directors Company Culture
 * Our Science
   About FIT-Ig®
 * Pipeline
   Pipeline
 * Partnering
   Partnering Strategy Existing Partnerships
 * News & Events
   News Events
 * Career
   EpimAb people Job opportunity



 * Who We Are
   About EpimAb Management Team Board of Directors Company Culture
 * Our Science
   About FIT-Ig®
 * Pipeline
   Pipeline
 * Partnering
   Partnering Strategy Existing Partnerships
 * News & Events
   News Events
 * Career
   EpimAb people Job opportunity

CN | EN

Bispecific
Antibody - The Way They Should Be

Advancing
Bispecifics to the Next Stage

Bispecific
Antibody - The Way They Should Be

Advancing
Bispecifics to the Next Stage

Bispecific
Antibody - The Way They Should Be

Advancing
Bispecifics to the Next Stage



Our Science
EpimAb's Proprietary Bispecific Platform : FIT-Ig®


Similar manufacturing convenience to monoclonal antibodies
Solubility comparable to monoclonal antibodies
Widely applicable to
multiple targets
Preserve the functions and properties of the monoclonal antibody
Tissue penetration
similar to monoclonal
antibodies
Production convenience
similar to monoclonal
antibodies





Pipeline
We have a robust and sustainable pipeline with 4 clinical stage assets (EMB-01,
EMB-02 , EMB-06 and EMB-09) and more than 10 preclinical stage candidates. Our
proprietary FIT-Ig® platform and other technical capabilities enable us to
target three strategic oncology areas (tumor targeting, dual checkpoint
inhibitors, immune cell engagers) and maintain our strong momentum to advance
additional preclinical assets to the clinic.
EMB-02


Preclinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
EMB-01
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary
FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is
being studied in Phase I/II clinical trials in NSCLC as well as several GI
indications in the U.S. and China.
EGFR/cMET in NSCLC, Monotherapy

EMB-01
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary
FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is
being studied in Phase I/II clinical trials in NSCLC as well as several GI
indications in the U.S. and China.
EGFR/cMET in NSCLC, Combo with Tagrisso®

EMB-01
EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary
FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is
being studied in Phase I/II clinical trials in NSCLC as well as several GI
indications in the U.S. and China.
EGFR/cMET in GI Cancers, Monotherapy

EMB-02
EMB-02 is a bispecific antibody targeting human programmed cell death protein 1
(PD-1) and lymphocyte-activation gene 3 (LAG-3) and is being evaluated in
advanced solid tumors. This antibody is designed to target human PD-1 and LAG-3
concomitantly or independently and disrupt the immune suppression mediated by
both pathways, thereby restoring T-cell effector function and enhancing
anti-cancer activity. Currently, a global Phase I/II study is ongoing with sites
opened in US, Australia, and China.
PD-1/LAG-3 in Solid Tumor

EMB-06
EMB-06 is a recombinant humanized bispecific antibody targeted against B cell
maturation antigen (BCMA) and cluster of differentiation 3 (CD3). Upon binding
to BCMA on tumor cell surface, EMB-06 can recruit and activate CD3 expressing T
lymphocytes, thereby mediating the killing effect of T lymphocytes on tumor
cells. Currently, a global Phase I/II study is enrolling patients in Australia
and China.
BCMA/CD3 in Multiple Myeloma

EMB-09
EMB-09 is a novel bispecific antibody developed based on EpimAb’s proprietary
FIT-Ig® platform to block PD-1/PD-L1 inhibitory signaling, and conditionally
activate T effector cells by stimulating OX40 through PD-L1 dependent cross
linking. EMB-09 showed superior immune cell activation in comparison with the
mAb combinations. Its unique OX40 binding epitope could improve the therapeutic
window, and silenced Fc effector function can avoid T effector cell depletion.
PD-L1/OX40 in Solid Tumor

EMB-07
EMB-07 is a T cell redirecting bispecific antibody by targeting a novel tumor
associated antigen (ROR1) and cluster of differentiation 3 (CD3). EMB-07 is
designed based on EpimAb’s proprietary bispecific antibody platform. Upon
binding to TAA on the tumor cell surface, EMB-07 can recruit and activate CD3
expressing T lymphocytes, thereby promoting the cytotoxic effect of T
lymphocytes. EMB-07 showed a promising preclinical efficacy and safety profile.
IND submission is expected in 2022.
ROR1/CD3 in Solid Tumor & Hematologic Malignancies




News
2024-03-06
EpimAb Biotherapeutics to Present Late-breaking Abstract on Preclinical Results
of EMB-07 at the 2024 American Association for Cancer Research Annual Meeting

2023-11-01
EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human
Data of EMB-06 at 2023 SITC Annual Meeting

2023-10-12
EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License
Agreement


Who We Are
EpimAb Biotherapeutics is a clinical stage biopharmaceutical company with
research and manufacturing facilities in Shanghai and Suzhou. With our unique
and proprietary platform technology called FIT-Ig® (Fabs-In-Tandem
Immunoglobulin) that is able to generate bispecific molecules with antibody-like
properties, we are creating a pipeline of novel therapeutics focused around
immuno-oncology and other disease areas with high unmet need.

EpimAb people
Platform Introduction
Management Team
Company Culture
Partnering Strategy



Contact
Shanghai
Adress
6th Floor, Building 2, Jinchuang Building, 702 Zhongke Road, Zhangjiang
High-tech Park, Shanghai, 201204, China
Phone
+86-21-61951000
Email
contact@epimab.com
shanghai

 * 
 * 
 * 
 * 
 * 
 * 

Accessibility Policy | Disclaimer | Privacy
COPYRIGHT © 2020 EPIMAB BIOTHERAPEUTICS, INC 备案号：沪ICP备16036337号-2
Powered By MANRO